The American Cancer Society estimates that approximately 16,600 new cases of myeloma are diagnosed each year in the United States. Bone pain is the most common early symptom of myeloma. Most patients feel pain in their back or ribs, but it can occur in any bone. The pain is usually made worse by movement.

Patients fatigue more easily and often feel weak. They may also have a pale complexion from anemia which is a common medical problem for patients with myeloma and may contribute to the fatigue. If the disease progresses, the concentration of normal cells in the blood may also decrease. Headaches, bruising, nose bleeding, gastrointestinal bleeding, and tingling or numbness in extremities are all symptoms of myeloma.

Patients may have repeated infections because antibodies to invading viruses, bacteria or other disease agents are not made efficiently of in adequate amounts. Urinary tract, bronchial, lung, skin, or other sites of infection may be the first sign of the disease. In addition, recurrent infections may complicate the course of the disease.

Cancer drug Gleevec, used for the treatment of chronic myeloid leukemia (CML), has been pulled out of another round of testing so it can get to work stopping the return of a rare stomach cancer. It's that good, according to findings announced on Thursday.

The promise of Gleevec should make it standard treatment for people with gastrointestinal stromal tumors (GIST), a stomach and intestine cancer diagnosed in 5,000 to 6,000 Americans each year.

The drug has already been used for patients whose disease is too advanced for surgery. Now it will be used for those whose tumors can be removed. The drug will be administered for at least one year post-surgery.

More than 600 people participated in this Gleevec trial. Each person took either Gleevec or a sugar pill for one year after surgery. After the one-year mark, cancer returned in 17 percent of people taking the sugar pill and in 3 percent of people taking the actual drug.

Since 50 to 90 percent of GIST cases recur over time, this is great news, say researchers who call Gleevec a highly targeted cancer drug with few side effects.

As of today, cancer patients in Britain have a new drug Sutent (sunitinib) available to them in the treatment for advanced kidney cancer and GIST, a rare gastrointestinal cancer. Sutent might become available in the future in the treatment of breast, lung and pancreatic cancers.

Called a smart drug, it offers a two-pronged approach in starving tumors of nutrients and shutting down the signaling of an enzyme that tells cancer cells to multiply.

There is some discussion that because of the cost of the drug, $4,500 a month per patient, the National Health Service (NHS) is planning to limit its availability. Sutent will be prescribed after other more traditional cancer drugs and treatment have failed for kidney and gastrointestinal cancer patients.

On July 20 in Portland, Oregon, Pearl Jam held a benefit concert for the Northwest Chapter of the Crohn's and Colitis Foundation of America (CCFA) to raise awareness for a disease no one likes to discuss. Pearl Jam guitarist Mike McCready was diagnosed with Crohn's disease and ulcerative colitis twenty years ago and has gone public with what he personally felt for many years was an embarrassing disease.

McCready, a spokesperson for the NW Chapter of CCFA, said, "Having struggled with Crohn's disease for more than 20 years and experienced first hand difficulties in getting a diagnosis and treatment, I want to help others learn about the disease, how it is affecting them and how to find ways to cope."

UCB, a leading global biopharmaceutical company that recently launched Crohns and Me, an information and resource website for people with Crohn's disease, joined with CCFA, in sponsoring the Pearl Jam Portland benefit concert.